Pharmacokinetics of teniposide in patients with ovarian cancer

M. D'Incalci, C. Rossi, C. Sessa, R. Urso, M. Zucchetti, P. Farina, C. Mangioni

Research output: Contribution to journalArticlepeer-review


Pharmacokinetics of teniposide (VM26) after each of three doses were investigated by high-performance liquid chromatographic assay in eight patients with ovarian cancer with normal liver and renal functions. Treatment consisted of a first dose of 100 mg/m2 iv as a 1-hour infusion (Day 1), a second dose of 150 mg/m2 iv as a 1-hour infusion (Day 8), and a third dose of 150 mg/m2 as an approximately 1-day infusion (Day 22). Disappearance of VM26 from plasma followed a biexponential decay pattern. The mean terminal half-life (± SE) was 6.9 ± 0.9 hours after the first dose, 6.1 ± 0.7 hours after the second dose, and 9.7 ± 1.4 hours after the third dose. VM26 levels in ascites were lower than those in plasma in the first hours after drug administration, but by 24 hours they were similar or slightly higher. Urinary elimination of VM26 as unchanged drug amounted to <10% of the dose.

Original languageEnglish
Pages (from-to)73-77
Number of pages5
JournalCancer Treatment Reports
Issue number1
Publication statusPublished - 1985

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Pharmacokinetics of teniposide in patients with ovarian cancer'. Together they form a unique fingerprint.

Cite this